More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor Conference
WASHINGTON, D.C. (December 15, 2014) - The Biotechnology Industry Organization (BIO) today announced the preliminary list of presenting companies for the 17th Annual BIO CEO & Investor Conference to be held February 9-10, 2015 in New York City. Presenting companies are hand-selected for the event, and consist of a selection of mid-to-large cap established public companies from around the globe. The participating companies typically have a clinical stage program focused on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.
“The industry is currently experiencing another banner year for biotech IPOs. With 79 IPOs year to date, we are nearly double where we were this time last year. We are thrilled to be hosting one-quarter of the 2014 IPO class as presenting companies at the BIO CEO & Investor Conference,” said BIO President and CEO Jim Greenwood.
In addition, to spotlight both established public and late-stage private companies at the BIO CEO & Investor Conference, BIO hosted the Buzz of BIO competition. This contest recognizes highly innovative companies in the biotech sector. A new element to this year’s CEO conference and modeled after the Buzz of BIO contest held in conjunction with the BIO International Convention, the campaign drew 18 nominees and pulled in nearly 800 votes. Winners are given the opportunity to present their story to industry leaders at the event. The winners are:
Most Distinguished Public Company
Synthetic Biologics, Inc. is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
Most Promising Private Company
Diffusion Pharmaceuticals is a clinical-stage biotech company developing new, small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action.
Below is the full list of companies planning to present at this year’s conference:
Public Companies:
• Advaxis
• Agenus
• Alkermes
• Athersys Inc.
• Biocept
• Biotron
• BrainStorm Cell Therapeutics
• Chimerix
• Codexis
• Exelixis
• GENFIT
• GenSpera
• NeoStem
• Newron Pharmaceuticals S.p.A.
• Ocata Therapeutics
• OXiGENE
• PAION AG
• Provectus Biopharmaceuticals
• pSiVida
• Relypsa
• Trevena
• Verastem
Private Companies:
• BeiGene
• BioXcel
• Kinemed
• MaxCyte
• Neurovance Inc.
To learn more about the BIO CEO & Investor Conference, including registration, programming and partnering information, please visit here.
Complimentary registration is available to qualified institutional (buy and sell-side), private equity or venture capital investors. Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies. Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.
Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials. To complete your registration, visit here.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks BMO Capital Markets, HC Wainwright & Co., JMP Securities, Lazard and ROTH Capital Partners, LLC.
###